Sanofi SA (SASY.PA): 2Q26 EPS beat aided by Dupixent one-off. Raised FY26 guide. More R&D projects cut. New CEO comments in line.

Research evidence excerpt

Sanofi SA (SASY.PA): 2Q26 EPS beat aided by Dupixent one-off. Raised FY26 guide. More R&D projects cut. New CEO comments in line.

Sanofi SA (SASY.PA)

30 July 2026 Citi Research

limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting

standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less

liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may

have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S.

investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but

investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from

the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from

the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the

Product in the United States. Any orders by US investors resulting from the information contained in the Product may be

placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first

named author is employed by.

The Product is made available in Australia through Citigroup Global Markets Australia Pty Limited. (ABN 64 003 114 832 and

AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission.

Citigroup Centre, 2 Park Street, Sydney, NSW 2000.